The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
10 | 33 | 38 | 23 |
Growth
|
21 | 13 | 33 | 35 |
Safety
|
99 | 99 | 51 | 51 |
Sentiment
|
49 | 14 | 57 | 64 |
|
37 | 37 | 6 | 32 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
81 | 7 | 1 | 15 |
Opinions Change
|
50 | 50 | 83 | 50 |
Pro Holdings
|
n/a | 8 | 39 | 72 |
Market Pulse
|
42 | 55 | 74 | 74 |
Sentiment
|
49 | 14 | 57 | 64 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
10 | 33 | 38 | 23 |
Growth
|
21 | 13 | 33 | 35 |
|
99 | 99 | 51 | 51 |
Combined
|
41 | 41 | 94 | 94 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
89 | 89 | 89 | 45 |
Price vs. Earnings (P/E)
|
1 | 3 | 5 | 6 |
Price vs. Book (P/B)
|
77 | 88 | 89 | 77 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
10 | 33 | 38 | 23 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
1 | 1 | 1 | 3 |
Profit Growth
|
60 | 14 | 29 | 94 |
Capital Growth
|
3 | 18 | 100 | 83 |
Stock Returns
|
39 | 31 | 29 | 3 |
Growth
|
21 | 13 | 33 | 35 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
100 | 100 | 100 | 100 |
Refinancing
|
99 | 98 | 99 | 95 |
Liquidity
|
1 | 1 | 69 | 69 |
|
99 | 99 | 51 | 51 |
Discover high‑ranked alternatives to Atea Pharmaceuticals and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.